Somatic pharmacogenomics of gastrointestinal stromal tumor

Abstract

Gastrointestinal stromal tumors (GISTs) are rare entities, which, however, represent the most common mesenchymal tumor of the gastrointestinal tract. The discovery of gain of function mutations on KIT and PDGFRA receptor genes led to a deep revolution in the knowledge of this tumor. This paved the way to the introduction of imatinib and other tyrosine-kinase inhibitors (TKIs), which terrifically revolutionized the prognosis of GIST patients. Currently, it is well established that tumor mutational status is the main player in clinical outcome; however, with the research advances, it has been slowly understood that GIST landscape is more complex than expected and the TKIs available are not effective for all the GIST subtypes. For this reason, in the era of tailored/personalized medicine, each GIST patient should be considered individually and genetic consult should be the first step to take in consideration in the therapeutic decision making process.

Keywords

Gastrointestinal stromal tumor / imatinib / pharmacogenomics / pharmacogenetics / tyrosine-kinase inhibitors

References

[1] Mei L,Idowu M,Boikos SA.Advances and challenges on management of gastrointestinal stromal tumors..Front Oncol2018;8:135 PMCID:PMC5949718

[2] Corless CL,Heinrich MC.Biology of gastrointestinal stromal tumors..J Clin Oncol2004;22:3813-25

[3] Hirota S,Moriyama Y,Nishida T.Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors..Science1998;279:577-80

[4] Ravegnini G,Angelini S.Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia..Expert Opin Drug Metab Toxicol2016;12:733-42

[5] Ricci R,Rindi G.GISTogram: a graphic presentation of the growing GIST complexity..Virchows Arch2013;463:481-7

[6] Miettinen M.Gastrointestinal stromal tumors..Gastroenterol Clin North Am2013;42:39 PMCID:PMC3644178

[7] Nannini M,Astolfi A,Pantaleo MA.The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)..J Transl Med2017;15:113 PMCID:PMC5442859

[8] Mei L,Faber AC,Grossman SR.Gastrointestinal stromal tumors: the GIST of precision medicine..Trends Cancer2018;4:74-91

[9] Boikos SA,Killian JK,Weldon CB.Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the national institutes of health gastrointestinal stromal tumor clinic..JAMA Oncol2016;2:922-8 PMCID:PMC5472100

[10] Corless CL,Heinrich MC.Gastrointestinal stromal tumours: origin and molecular oncology..Nat Rev Cancer2011;11:865-78

[11] Indio V,Tarantino G,Patterson J.Integrated molecular characterization of gastrointestinal stromal tumors (GIST) harboring the rare D842V mutation in PDGFRA gene..Int J Mol Sci2018;19:732 PMCID:PMC5877593

[12] Angelini S,Fletcher JA,Hrelia P.Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy..Pharmacogenomics2013;14:941-56

[13] de Melo Maia B,Rodrigues IS,Cestari FM.Prognostic significance of c-KIT in vulvar cancer: bringing this molecular marker from bench to bedside..J Transl Med2012;10:150 PMCID:PMC3478999

[14] Hirota S,Nishida T,Kinoshita K.Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors..Gastroenterology2003;125:660-7

[15] Heinrich MC,Duensing A,Chen CJ.PDGFRA activating mutations in gastrointestinal stromal tumors..Science2003;299:708-10

[16] Huss S,Trautmann M,Hartmann W.Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy..Expert Rev Anticancer Ther2015;15:623-8

[17] Kumar R,Hemminki K.Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9..Oncogene2003;22:9217-24

[18] Scherer D,Angelini S,Sucker A.Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors..J Invest Dermatol2010;130:2844-8

[19] Dankner M,Rajkumar S,Watson IR.Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations..Oncogene2018;37:3183-99

[20] Ravegnini G,Sammarini G,Castri F.Gastrointestinal juvenile-like (inflammatory/hyperplastic) mucosal polyps in neurofibromatosis type 1 with no concurrent genetic or clinical evidence of other syndromes..Virchows Arch2019;474:259-64

[21] Urbini M,Indio V,Corless CL.SDHC methylation in gastrointestinal stromal tumors (GIST): a case report..BMC Med Genet2015;16:87 PMCID:PMC4587653

[22] Miettinen M.Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review..Int J Biochem Cell Biol2014;53:514-9 PMCID:PMC4112081

[23] Pantaleo MA,Urbini M,Paterini P.Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST..Eur J Hum Genet2014;22:32-9 PMCID:PMC3865408

[24] Casali PG,Bauer S,Bielack S.Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up..Ann Oncol2018;29(Supplement_4):iv68-78

[25] Akahoshi K,Koga T.Current clinical management of gastrointestinal stromal tumor..World J Gastroenterol2018;24:2806-17 PMCID:PMC6048423

[26] ESMO/European Sarcoma Network Working GroupGastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up..Ann Oncol2014;25 Suppl 3:iii21-6

[27] Demetri GD,Blanke CD,Eisenberg B.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors..N Engl J Med2002;347:472-80

[28] Maleddu A,Nannini M,Saponara M.Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review)..Oncol Rep2009;21:1359-66

[29] Demetri GD,Garrett CR,Shah MH.Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial..Lancet2006;368:1329-38

[30] George S,Heinrich MC,Zhu M.Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: A multicenter phase II trial..J Clin Oncol2012;30:2401-7

[31] Papaetis GS.Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies..BioDrugs2009;23:377-89

[32] Vincenzi B,Grignani G,Gasperoni S.Rechallenge in advanced GIST progressing to imatinib, sunitinib and regorafenib: an Italian survey..J Clin Oncol2017;35:11038

[33] Housman G,Heerboth S,Longacre M.Drug resistance in cancer: an overview..Cancers (Basel)2014;6:1769-92 PMCID:PMC4190567

[34] Lee JH,Choi JW.Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis..J Gastrointestin Liver Dis2013;22:413-8

[35] Künstlinger H,Merkelbach-Bruse S,Kleine MA.Gastrointestinal stromal tumors with KIT exon 9 mutations: update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing..Am J Surg Pathol2013;37:1648-59

[36] Debiec-Rychter M,Le Cesne A,Hohenberger P.KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours..Eur J Cancer2006;42:1093-103

[37] Heinrich MC,Corless CL,Borden EC.Correlation of kinase genotype and clinical outcome in the North American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and leukemia group B and Southwest oncology group..J Clin Oncol2008;26:5360-7 PMCID:PMC2651078

[38] Casali PG,Le Cesne A,Blay JY.Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European organisation for research and treatment of cancer, Italian sarcoma group, and Australasian gastrointestinal trials group intergroup phase III randomized trial on imatinib at two dose levels..J Clin Oncol2017;35:1713-20

[39] Kikuchi H,Setoguchi T,Ohta M.Rapid relapse after resection of a sunitinib-resistant gastrointestinal stromal tumor harboring a secondary mutation in exon 13 of the c-KIT gene..Anticancer Res2012;32:4105-9

[40] Corless CL,Griffith D,McGreevey L.PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib..J Clin Oncol2005;23:5357-64

[41] Blay JY,Hohenberger P,Rutkowski P.A randomized, double-blind, placebo-controlled, phase III study of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in PDGFRA: the CrenoGIST study..J Clin Oncol2017;35:TPS11080

[42] Klug LR,Heinrich MC.Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases..Pharmacol Ther2018;191:123-34

[43] Heinrich MC,Blanke CD,Borden EC.Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results..JAMA Oncol2017;3:944-52 PMCID:PMC5727908

[44] Oppelt PJ,Van Tine BA.Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review..J Gastrointest Oncol2017;8:466-73 PMCID:PMC5506287

[45] Gounder MM.Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor..Cancer Chemother Pharmacol2011;67:25-43 PMCID:PMC3275340

[46] Aparicio-Gallego G,Figueroa A,Valladares-Ayerbes M.New insights into molecular mechanisms of sunitinib-associated side effects..Mol Cancer Ther2011;10:2215-23

[47] Heinrich MC,Corless CL,Harlow A.Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor..J Clin Oncol2008;26:5352-9 PMCID:PMC2651076

[48] Ben-Ami E,von Mehren M,Corless CL.Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy..Ann Oncol2016;27:1794-9 PMCID:PMC6279099

[49] Miranda C,Molinari F,Anania MC.KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors..Clin Cancer Res2012;18:1769-76

[50] Franck C,Franke S,Canbay A.The BRAF status may predict response to sorafenib in gastrointestinal stromal tumors resistant to imatinib, sunitinib, and regorafenib: case series and review of the literature..Digestion2019;99:179-84

[51] Falchook GS,Heinrich MC,Patterson J.BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance..Oncotarget2013;4:310-5 PMCID:PMC3712576

[52] Mussi C,Gronchi A,Hohenberger P.Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1..Clin Cancer Res2008;14:4550-5

[53] Lee JL,Ryu MH,Chang HM.Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1..Dig Dis Sci2006;51:1043-6

[54] Miettinen M,Sobin LH.Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases..Am J Surg Pathol2006;30:90-6

[55] Caudle KE,Whirl-Carrillo M,Relling MV.Evidence and resources to implement pharmacogenetic knowledge for precision medicine..Am J Heal Pharm2016;73:1977-85 PMCID:PMC5117674

[56] Ravegnini G,Sammarini G,Biasco G.Personalized medicine in gastrointestinal stromal tumor (GIST): clinical implications of the somatic and germline DNA analysis..Int J Mol Sci2015;16:15592-608 PMCID:PMC4519915

[57] Eechoute K,Burger H,Schiavon G.Drug transporters and imatinib treatment: implications for clinical practice..Clin Cancer Res2011;17:406-15

[58] Verboom MC,Swen JJ,Bovée JVMG.Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib..Eur J Cancer2017;86:226-32

[59] Zhang Q,Qian Y,Li Q.Association of imatinib plasma concentration and single-nucleotide polymorphisms with adverse drug reactions in patients with gastrointestinal stromal tumors..Mol Cancer Ther2018;17:2780-7

[60] Liu J,Chen H,Lu W.Genetic polymorphisms contribute to the individual variations of imatinib mesylate plasma levels and adverse reactions in chinese GIST patients..Int J Mol Sci2017;18:603 PMCID:PMC5372619

[61] Kloth JSL,Swen JJ,Sleijfer S.Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib..Pharmacogenomics J2018;18:49-55

[62] Saif MW,Maloney A.Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor..Ann Gastroenterol2016;29:551-6 PMCID:PMC5049570

[63] Yang J,Nishioka C,Hanazaki K.Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene..Int J cancer2012;130:959-66

[64] Jasek K,Holubekova V,Plank L.Epigenetics: an alternative pathway in GISTs tumorigenesis..Neoplasma2018;65:477-93

[65] Yun S,Kwon Y,Bauer S.Survivin is a novel transcription regulator of KIT and is downregulated by miRNA-494 in gastrointestinal stromal tumors..Int J cancer2018;142:2080-93 PMCID:PMC5900938

[66] Zhang Z,Guan RY,Jiang FQ.Identification of critical microRNAs in gastrointestinal stromal tumor patients treated with Imatinib..Neoplasma2018;65:683-92

[67] Pantaleo MA,Astolfi A,Nannini M.Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors..Epigenomics2016;8:1347-66

[68] Ravegnini G,Simeon V,Astolfi A.An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor..Pharmacogenomics J2018;

[69] Angelini S,Nannini M,Musti M.Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome..Eur J Hum Genet2015;23:817-23 PMCID:PMC4795063

[70] Ravegnini G,Simeon V,Sammarini G.Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome..Tumour Biol2016;37:13413-23

[71] Angelini S,Ravegnini G,Cavrini G.Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy..Pharmacol Res2013;68:1-6